Tonix Pharmaceuticals Holding Corp. (TNXP) recently announced certain preliminary financial information and selected preliminary operating results for the quarter ended June 30, 2025. The company exited the second quarter of 2025 with approximately $125.3 million in cash and cash equivalents and subsequently raised an additional $50.6 million in July 2025, which is sufficient to fund operations into the third quarter of 2026. This report also provides an in-depth look at TNX-1500, a third-generation anti-CD40 ligand (CD40L) antibody, as a therapy to prevent allograft and bone marrow transplant rejection and a treatment for autoimmune diseases. The company recently reported positive results from a Phase 1 clinical trial showing the ability of TNX-1500 to prevent a response to a test immunogen and has previously reported positive results from multiple pre-clinical animal model studies showing the prevention of organ transplant rejection. The company is preparing for a Phase 2 clinical trial in the prevention of kidney transplant rejection, with the potential to expand to the multi-billion-dollar autoimmune disease therapy markets.
